- Autor
-
Pracoviště
Center for Chronic Immunodeficiency U... 1 Department of Biostatistics DOCS Inte... 1 Department of Clinical Immunology and... 1 Department of Medical Affairs Bristol... 1 Department of Medical Immunoscience B... 1 Department of Real World Research Chi... 1 Department of Rheumatology Schlosspar... 1 Department of Rheumatology St Joseph'... 1 Department of Rheumatology University... 1 Department of Rheumatology University... 1 Department of Rheumatology VU Univers... 1 Department of Rheumatology and Immuno... 1 Excelya Boulogne Billancourt France 1 Institute of Rheumatology and Clinic ... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
Center for Chronic Immunodeficiency U... 1 Department of Biostatistics DOCS Inte... 1 Department of Clinical Immunology and... 1 Department of Medical Affairs Bristol... 1 Department of Medical Immunoscience B... 1 Department of Real World Research Chi... 1 Department of Rheumatology Schlosspar... 1 Department of Rheumatology St Joseph'... 1 Department of Rheumatology University... 1 Department of Rheumatology University... 1 Department of Rheumatology VU Univers... 1 Department of Rheumatology and Immuno... 1 Excelya Boulogne Billancourt France 1 Institute of Rheumatology and Clinic ... 1
- Formát
- Publikační typ
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
NLK
Directory of Open Access Journals
od 2015
Free Medical Journals
od 2015
PubMed Central
od 2015
Europe PubMed Central
od 2015
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2015-01-01
Open Access Digital Library
od 2015-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2015
PubMed
26925253
DOI
10.1136/rmdopen-2015-000228
Knihovny.cz E-zdroje
INTRODUCTION: Prolonged glucocorticoid use may increase the risk of adverse safety outcomes, including cardiovascular events. The European League Against Rheumatism and the Canadian Rheumatology Association advise tapering glucocorticoid dose as rapidly as clinically feasible. There is a paucity of published data on RA that adequately describe concomitant treatment patterns. METHODS: ACTION (AbataCepT In rOutiNe clinical practice) is a non-interventional cohort study of patients from Europe and Canada that investigated the long-term retention of intravenous abatacept in clinical practice. We assessed concomitant glucocorticoids in patients with established RA who had participated in ACTION and received ≥1 biological agent prior to abatacept initiation. RESULTS: The analysis included 1009 patients. Glucocorticoids were prescribed at abatacept initiation in 734 (72.7%) patients at a median 7.5 mg/day dose (n=692). Of the patients who remained on abatacept at 24 months, 40.7% were able to decrease their dose of glucocorticoids, including 26.9% who decreased their dose from >5 mg/day to ≤5 mg/day. CONCLUSION: Reduction and/or cessation of glucocorticoid therapy is possible with intravenous abatacept in clinical practice.
- Publikační typ
- časopisecké články MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.